Aurinia Pharmaceuticals Inc
Last updated September 27, 2026
Organization details
- Legal name
- Aurinia Pharmaceuticals Inc
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Headquarters city
- Edmonton
- Headquarters country
- Canada
- Fiscal year end
- December
- Ticker symbol
- AUPH
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001600620
- EIN
- 98-1231763
Board of directors
-
Brinda Balakrishnan · DirectorSince 2023
-
Craig A. Johnson · DirectorSince 2024
-
Daniel Billen · DirectorSince 2023
-
David R.w. Jayne · DirectorSince 2023
-
George M. Milne Jr. · DirectorSince 2023
-
Jeffrey Allen Bailey · DirectorSince 2023
-
Jill Leversage · DirectorSince 2023
-
Joseph P. Hagan · DirectorSince 2023
-
Karen L. Smith · DirectorSince 2023
- Since 2025
-
Kevin Tang · Director · Chief Executive OfficerSince 2024
-
Peter Greenleaf · Director · Chief Executive OfficerSince 2023
-
R. Hector MacKay-Dunn · DirectorSince 2023
-
Robert T. Foster · DirectorSince 2023
-
Tina Susan Nova · DirectorSince 2025
Chief executives
Peter Greenleaf
· Chief Executive Officer
Dates unknown
Kevin Tang
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of May 15, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
75.9%
-
76.9%
-
79.3%
-
80.2%
-
85.9%
Board connections
6 of this board's directors also sit on 11 other boards.
- via George M. Milne Jr.
- via Tina Susan Nova
- via Karen L. Smith
- via Tina Susan Nova
- via Craig A. Johnson
- via Peter Greenleaf
- via Karen L. Smith
- via Kathleen Goetz
- via Kathleen Goetz
- via Kathleen Goetz
- via Kathleen Goetz
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $25,144,033
- 11 purchases by 1 insider
- Sold, last 12 months
- $546,373
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 10, 2026 | Robertson Stephen P. Officer (Chief Legal Officer) | Open-market sale | −11,939 | $15.95 | $190,427 |
| Aug 21, 2026 | Robertson Stephen P. Officer (Chief Legal Officer) | Open-market sale | −20,975 | $16.97 | $355,946 |
| Jun 2, 2026 | Kevin Tang Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +206,005 | $15.28 | $3,147,756 |
| Jun 1, 2026 | Kevin Tang Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +343,521 | $15.28 | $5,249,001 |
| Jun 1, 2026 | Kevin Tang Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +99 | $15.34 | $1,519 |
| May 29, 2026 | Kevin Tang Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +2,299 | $15.35 | $35,290 |
| May 29, 2026 | Kevin Tang Director, Officer (Chief Executive Officer), 10% owner | Open-market purchase | +262,682 | $15.31 | $4,021,661 |
| May 18, 2026 | Robertson Stephen P. Officer (Chief Legal Officer) | Grant or award | +115,541 | — | — |
| May 18, 2026 | Hearne Michael S Officer (Chief Financial Officer) | Grant or award | +116,144 | — | — |
| May 18, 2026 | Cole Ryan Officer (Chief Operating Officer) | Grant or award | +116,144 | — | — |
| Mar 6, 2026 | Keenan Greg Officer (SVP, Chief Medical Officer) | Shares withheld for tax | −8,069 | $14.32 | $115,548 |
| Mar 3, 2026 | Kevin Tang Director | Open-market purchase | +184,208 | $14.22 | $2,619,438 |
| Mar 2, 2026 | Miller Joseph M Officer (Chief Financial Officer) | Shares withheld for tax | −37,511 | $14.21 | $533,031 |
| Mar 2, 2026 | Donley Matthew Maxwell Officer (Chief Operating Officer) | Shares withheld for tax | −40,761 | $14.21 | $579,214 |
| Mar 2, 2026 | Peter Greenleaf Director, Officer (Chief Executive Officer) | Shares withheld for tax | −100,890 | $14.21 | $1,433,647 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.